Nykode Therapeutics AS (NYKD.OL)

NOK 3.19

(-4.61%)

Operating Expenses Summary of Nykode Therapeutics AS

  • Nykode Therapeutics AS's latest annual operating expenses in 2023 was 71.4 Million USD , up 28.25% from previous year.
  • Nykode Therapeutics AS's latest quarterly operating expenses in 2024 Q2 was 12.33 Million USD , down -24.95% from previous quarter.
  • Nykode Therapeutics AS reported a annual operating expenses of 556.84 Million USD in annual operating expenses 2022, up 51.47% from previous year.
  • Nykode Therapeutics AS reported a annual operating expenses of 367.63 Million USD in annual operating expenses 2021, up 17.9% from previous year.
  • Nykode Therapeutics AS reported a quarterly operating expenses of 168.98 Million USD for 2024 Q1, down -14.27% from previous quarter.
  • Nykode Therapeutics AS reported a quarterly operating expenses of 714.14 Million USD for 2023 FY, up 28.25% from previous quarter.

Annual Operating Expenses Chart of Nykode Therapeutics AS (2023 - 2016)

Historical Annual Operating Expenses of Nykode Therapeutics AS (2023 - 2016)

Year Operating Expenses Operating Expenses Growth
2023 71.4 Million USD 28.25%
2022 556.84 Million USD 51.47%
2021 367.63 Million USD 17.9%
2020 311.81 Million USD 154.14%
2019 122.69 Million USD 0.0%
2018 - NOK -100.0%
2017 2.00 NOK 100.0%
2016 1.00 NOK 0.0%

Peer Operating Expenses Comparison of Nykode Therapeutics AS

Name Operating Expenses Operating Expenses Difference
Arctic Bioscience AS -5730.00 NOK 1246260.558%
Aqua Bio Technology ASA 18.46 Million NOK -286.703%
ArcticZymes Technologies ASA 97.26 Million NOK 26.589%
BerGenBio ASA 192.17 Million NOK 62.843%
Hofseth BioCare ASA 156.04 Million NOK 54.24%
PCI Biotech Holding ASA 25.23 Million NOK -183.005%
Thor Medical ASA 7.16 Million NOK -897.137%
Ultimovacs ASA 215.73 Million NOK 66.902%